A Randomized, Double-Blind, Placebo Controlled, Phase 2 Trial of Paclitaxel in Combination With AMG 386 in Subjects With Advanced Recurrent Epithelial Ovarian or Primary Peritoneal Cancer.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 10 Oct 2017
At a glance
- Drugs Trebananib (Primary) ; Paclitaxel
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Sponsors Amgen
- 02 Oct 2017 Planned End Date changed from 29 Sep 2017 to 29 Mar 2018.
- 10 Jun 2017 Biomarkers information updated
- 01 Mar 2017 Planned End Date changed from 1 Sep 2016 to 1 Sep 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History